Publicis Groupe is to acquire a majority stake in Watermelon Healthcare Communications Private Limited, a leading healthcare advertising agency in Mumbai, India. Post the stake acquisition, Watermelon will become part of Publicis Healthcare Communications Group (PHCG) and will be renamed Publicis Life Brands Watermelon. This transaction is subject to customary local closing conditions.
Watermelon is a

Cx Partners reported it had invested around Rs 188 crore in Thyrocare Technologies for the acquisition of a 30 per cent stake. Cx Partners, the private equity firm, will acquire the stake in the medical diagnostics firm, valuing Thyrocare Technologies Ltd at Rs 627 Crore. According to the firm, the funds to be accrued from

Fortis Healthcare Ltd, India’s fastest growing hospital network, announced the take over of Operations and Management of the 150 bed Vivekanand Hospital and Research Centre in Moradabad, Uttar Pradesh (UP). The move is in line with its strategy to strengthen its presence in India’s tier II cities. The addition of Vivekanand Hospital takes the Fortis

Opto Circuits Ltd announced it had bought the detection and diagnostics business of Unetixis Vascular. The firm said it had made the investment as a measure towards increasing the size of its portfolio and offering. The move is geared towards expanding the firm’s presence in the detection and diagnostics space and will go a long

Godrej Consumer Products Ltd is mulling domestic Indian acquisitions to bolster its growth. The firm, already having undertaken four overseas acquisitions this year alone, is interested in acquiring a number of domestic firms. Adi Godrej, chairman Godrej Consumers Products Ltd said the firm is keen on bolstering its Indian position and offering and will be

TA Associates is in discussions with Indian firm, Dr Lal Pathlabs for the acquisition of a 15% stake in Dr Lal Pathlabs from Sequoia Capital. The investment will see the US based TA Associates remit about Rs 170 crore for the acquisition. Sequoia Capital controls about 30% stake in Dr Lal Pathlabs and the deal

After losing in a biding war against a Malaysian firm for Parkway Holdings, a Singaporean company, Fortis Healthcare Thursday announced that it was still keen on undertaking more acquisitions in Asia. The company said it would particularly target healthcare companies in Asia as it expands its presence in the region and beyond. Malvinder Singh, Fortis

Super Religare Labs (SRL) Tuesday announced it had successfully completed talks for the acquisition of Piramal Diagnostics. The deal will see Super Religare takeover Piramal Diagnostics’ 107 labs, with the company’s current annual revenues generation pegged at more than Rs 200 crore. The new acquisition investment comes in the wake of Piramal Healthcare’s sell of

Swiss multi-national drug manufacturer, Roche Holding AG, announced that it intends to invest in the acquisition of diagnostic equipment makers and innovative diagnostic products in India. The Swiss giant said it would undertake the Indian investments through its subsidiary, Roche Diagnostics; in an investment acquisition that marks the drug makers first such move ever since